• Article highlight
  • Article tables
  • Article images

Article History

Received : 25-10-2023

Accepted : 30-10-2023



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 520

PDF Downloaded: 384


Get Permission Patil, Vadnere, Baviskar, Sarode, and Nimbalkar: Analytical and bio-analytical methods of rofecoxib: A comprehensive review


Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation in rheumatoid arthritis. Their analgesic and anti-inflammatory effects, as well as some of their chemo preventive effects, are attributed to their inhibition of cyclooxygenase (COX) enzymes, which turn arachidonic acid into prostaglandins.1 Rofecoxib is chemically 3-phenyl-4-(p-methylsulphonyl)-phenyl-(5H)-furan–2-one is a highly selective cyclooxygenase–2 (COX-2) inhibitor.2 Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) are the two types of the enzyme. Normal physiological processes mediated by prostaglandins, such as platelet aggregation and gastric cytoprotection, are controlled by COX-1. Gastric damage and platelet inhibition have been linked to nonselective NSAID’s COX-1 inhibition. It has been established that COX-2 plays a key role in the production of prostanoid mediators of pain and inflammation.2

In addition to treating acute migraine episodes with or without auras, rofecoxib is also used to treat adult cases of primary dysmenorrhea, rheumatoid arthritis, osteoarthritis, and acute pain.3

Figure 1

Depict the chemical structure of rofecoxib

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/869409d4-dabe-46da-b119-40a52ccdc4aeimage1.png

Mechanism of Action

The suppression of prostaglandin production appears to be the cause of the anti-inflammatory, analgesic and antipyretic actions of NSAIDs. These effects appear to be achieved by inhibiting the COX-2 isoenzyme at the sites of inflammation, which then results in a decrease in the manufacture of certain prostaglandins from their arachidonic acid precursors, however the precise mechanism of action has not yet been established. The COX-2 enzyme, which is crucial for the regulation of pain and inflammation, is specifically inhibited by rofecoxib. Rofecoxib does not prevent platelet aggregation, unlike non-selective NSAIDs. Affinity for COX-1 is also negligible to non-existent.4, 5

Pharmacokinetics

  1. Absorption: At clinically advised dosages of 12.5, 25, and 50 mg respectively rofecoxib had a mean oral bioavailability of 93%. 4

  2. Protein binding: 87%

  3. Metabolism: Rofecoxib is predominantly metabolized by cytosolic enzymes by reduction. The cis-dihydro and trans-dihydro derivatives of rofecoxib, which make up about 56% of the radioactivity collected in the urine, are the main metabolic products. 8.8% more of the dosage was recovered as the hydroxy derivative's glucuronide, which is a by-product of oxidative metabolism. In humans, rofecoxib's biotransformation into this metabolite can be partially reversed (5%). As COX-1 or COX-2 inhibitors, these metabolites are ineffective. Cytochrome P450 has a small impact on how rofecoxib is metabolized. 4

  4. Pharmacodynamics: In contrast to celecoxib, rofecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism. Like other NSAIDs, rofecoxib exhibits anti-inflammatory, analgesic, and antipyretic activity. NSAIDs appear to inhibit prostaglandin synthesis by inhibiting cyclooxygenase (COX), which is responsible for catalyzing the formation of prostanoids.4

Analytical Account of RFX

An extensive literature search revealed a variety of analytical methods, including UV/Visible Spectrophotometry, High-performance liquid chromatography (HPLC), High-performance thin layer chromatography (HPTLC), Liquid chromatography-mass spectrometry (LC-MS) and bioanalytical approaches, for the determination of RFX in bulk and pharmaceutical formulations. Celecoxib (CXB), Paracetamol (PCT), Diclofenac (DIC), Niflumic Acid (NIF), Mosapride Citrate (MSPC), and Tizanidine (TNZ) are all evaluated alone as well as in combination with RFX.

Figure 2

Different analytical methods implemented for the estimation of RFX in a bulk and pharmaceutical dosage form

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/869409d4-dabe-46da-b119-40a52ccdc4aeimage2.png

Bio-analytical method for RFX

A branch of analytical chemistry known as "bio-analysis" deals with the quantitative measurement of biotics (macromolecules, proteins, DNA, large-molecule drugs, metabolites) and xenobiotics (drugs and their metabolites) in biological systems. 6 The summary of the reported bioanalytical methods is shown in Table 1.

Table 1

Summary of bioanalytical methods for the determination of RFX in a single and combined dosage form

Sr. No.

Drug

Sample Matrix

Method

Column

Detection

Internal Standard

Ref

1

RFX

Human serum

HPLC

Novapak-C18 analytical column

254 nm

Diazepam

7

2

RFX

Bovine serum albumin microsphere

HPLC

C18 column

272 nm

***

8

3

RFX

Rat and Human Plasma

HPLC

C18 analytical column

272 nm

***

9

4

RFX

Bulk Drug, Tablets and Human Plasma

RP-HPLC

Spherisorb ODSI column

244 nm

Etodolac

10

5

RFX

Human Plasma

HPLC

BDS-Hypersil C18 analytical column

250 nm

***

11

6

RFX and CXB

Human plasma

HPLC

Zorbax SB-CN analytical column

254 nm

4-n-pentyl-phenyl-acetic acid

12

7

CEL, RFX DIC and NIF

Human serum

HPLC

C18 bonded silica column

254, 261, 282 and 288 nm

***

13

8

RFX

Human plasma

HPLC-MS

Nucleosil C8 guard column

***

Celecoxib

14

9

RFX

Human plasma

HPLC

Symmetry C18 column

250 to 375 nm

***

15

10

RFX

Human plasma

Solid-phase extraction

Waters Symmetry C18 analytical column

250 nm

***

16

11

RFX

Human plasma

HPLC-MS

C18 analytical column

***

***

17

12

RFX

Human plasma

HPLC-MS

C18 analytical column

***

***

18

UV-Visible spectroscopy method for RFX

The spectrophotometric methods have been accounted for the determination of RFX. The details of Spectrophotometry determination of basic principle, sample matrix, lambda max, solvent linearity range and the correlation coefficient are summarized in Table 2.

Table 2

Spectrophotometric methods used for determination of RFX in a single and combined dosage form

Sr. No.

Drug

Matrix

Solvent

Lambda Max (nm)

Linearity (μg/mL)

Correlation coefficient (R2)

Ref.

1

RFX

bulk and pharmaceutical formulations

Methanol

279 nm

2.5–30.0 ng/ml

0.9985

19

2

RFX and MSPC

Indivisual dosage form

Methanol

282 nm and 331 nm

10-50 ng/ml 2-10 ng/ml

0.9990 0.9996

20

Liquid-Chromatography-Mass Spectroscopy Methods (LC-MS) for RFX

The LC/MS combo has drawn a lot of attention recently for its enhanced performance in the detection of important analytes in challenging samples.21, 22, 23 A detailed analysis resulted in the separation of LC/MS interfaces into two categories: interfaces for indirect and direct input of column effluent. The column effluent is transferred mechanically from the indirect introduction contact to the MS vacuum. The transportation system is a prime example of an indirect introduction type of interface. The mass spectrometric vacuum system receives the column effluent directly through a tube in the direct introduction system. In general, the direct introduction seems to be the easiest way to connect LC and MS. 24 In this section, we have discussed the LC-MS methods for the determination of RFX in a dosage form Table 3.

Table 3

Summary of LC-MS methods for the determination of RFX in a single and combined dosage form

Sr. No

Drug

Matrix

Stationary Phase

Mobile Phase

Internal Standard

Linearity (mg/mL)

Ref.

1

RFX

***

Shimpak ods C 20 column

Acetonitrile/0.05% phosphoric acid (35:65)

***

2–36 mg/ml

25

2

RFX

Bulk and pharmaceutical dosage forms

Symmetry C18 analytical Column

Acetonitrile-water (50:50, v/v)

Chlorophenyl methyl sulphone

125 to 500 mg/ml

26

3

TZN and RFX

Tablets

Spherisorb ODS column

Triethylamine (pH adjusted to 2.5 using dilute orthophosphoric acid): acetonitrile 55:45% (v/v)

Nimesulide

0.1–0.5 mg/ml 1.2–6.0 mg/ml

27

High-performance liquid chromatography (HPLC) method for RFX

The specificity of the HPLC method is excellent and simultaneously sufficient precision is also attainable. However, it has to be stated that the astonishing specificity, precision, and accuracy are attainable only if wide-ranging system suitability tests are carried before the HPLC analysis. For this reason, the expense to be paid for the high specificity, precision, and accuracy is also high. The summary of the reported HPLC methods is shown in Table 4.

Table 4

4. Summary of HPLC methods for the determination of RFX in a single and combined dosage form

Sr. No.

Drug name

Column

Mobile phase

Lambda max(nm)

Linearity (μg/mL)

Retention time (min)

Flow rate (mL/min)

Detector

Ref.

1

RFX

C18 analytical column

Water: Acetonitrile (55:45 v/v)

366 nm

10-350 ng/ml

7.5 to 8 min

1 ml/min

Fluorescence

28

2

RFX

Column Apollo C18 column

Methanol and water (45:55 % v/v)

260 nm

24-120 mg/ml

2.379 ±0.02 min

0.8 ml/min

PDA

29

3

RFX

ODS C-18 column

Methanol: Water (50:50)

230 nm

2-40 mg/ml

7.79–8.00 min

1 ml/min

UV-Vis

30

4

RFX and TNZ

Luna C-18 column

Methanol: Phosphate buffer pH 3.5 (55:45 v/v)

240 nm

7.5-17.5 mg/ml and 0.6-1.4 mg/ml

4.53 min and 5.92 min

1 ml/min

UV-Vis

5

5

RFX and TNZ

Wakosil C-18 column

Acetonitrile: phosphate buffer pH 5.0 (50:50 v/v)

240 nm

50-200 mg/ml and 10-80 mg/ml

4.9 min and 12.2 min

0.5 ml/min

UV-Vis

31

6

PCT and RFX

Hypersil C-18 column

20mM phosphate buffer (pH 7.0±0.1): Acetonitrile (55:45 v/v)

254 nm

7-13 mg/ml and 0.35-0.65 mg/ml

2.61 min and 10.49 min

1 ml/min

UV-Vis

32

7

TNZ and RFX

Kromasil C-18 column

Phosphate buffer ph 5.5 and methanol (45:55 v/v)

235 nm

10-200 g/ml and 100-2000 g/ml

3.199 min and 7.109 min

1 ml/min

UV-Vis

33

High-performance thin layer chromatography (HPTLC) method for RFX

Thin-layer chromatography is a popular technique for the analysis of a wide variety of organic and inorganic materials, because of its distinctive advantages such as minimal sample clean-up, a wide choice of mobile phases, flexibility in sample distinction, high sample loading capacity and low cost. The summary of the reported HPTLC methods is shown in Table 5.

Table 5

Summary of HPTLC methods for the determination of RFX in a single and combined dosage form

Sr. No.

Drug

Stationary Phase

Mobile Phase

Detection

Linearity

Ref.

1

RFX and TZN

Precoated with silica gel 60F254 on aluminium sheets

Toluene: ethyl acetate: methanol: triethyl amine 6:3:0.5:0.1 (v/v/v/v)

235 nm

3.75 to 11.25 μg/spot 0.30 to 0.90 μg/spot

34

2

TZN and RFX

Merck HPTLC aluminium sheets of silica gel 60 F254

Toluene: methanol: acetone (7.5:2.5:1.0, v/v/v)

311 nm

10–100 ng/spot 100–1500 ng/spot

35

3

TZN and RFX

Precoated silica Gel G 60 F254 TLC plate

N- butyl acetate: formic acid: chloroform (6:4:2 v/v/v)

315 nm

2-10 mg/spot 16-80 mg/spot

36

Conclusion

The current review paper provides in-depth knowledge of the several analytical and bioanalytical methods developed for Rofecoxib, both individually and in combination. For analysis purposes, a variety of unique analytical procedures, including HPLC, HPTLC, LC-MS and UV spectroscopy, etc., have been reported. For the advantage of the researchers, the approach has been laid out in tabular form and includes details about the mobile phase, stationary phase, retention time, etc. The gathered information can be used to create future analytical methods for the bio-analysis of rofecoxib in pharmaceutical and biological formulations. Finally, it provides a chance to learn more about what has previously been accomplished as well as potential future plans and adjustments to further our knowledge of rofecoxib.

Abbreviations

  1. UV/VIS - Ultra violet/visible spectroscopy

  2. HPLC - High-performance liquid chromatography

  3. HPTLC - High-performance thin layer chromatography

  4. LC-MS - Liquid chromatography-mass spectroscopy

  5. RP - Reverse phase

  6. nm - Nanometer

  7. μg/mL - Micro gram per Milliliter

  8. PDA - Photo diode array

  9. CXB – Celecoxib

  10. RFX – Rofecoxib

  11. DIC – Diclofenac

  12. NIF – Niflumic Acid

  13. MSPC – Mosapride Citrate

  14. TNZ – Tizanidine

  15. PCT – Paracetamol

Source of Funding

None.

Conflict of Interest

The authors declare that no conflict of interest.

Acknowledgments

Authors are thankful to Smt. Sharadchandrika Suresh Patil College of Pharmacy, Chopda: 425107, Jalgaon (MH), India for providing necessary library facilities.

References

1 

E Niederberger C Manderscheid S Grösch H Schmidt C Ehnert G Geisslinger Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cellsBiochem Pharmacol200468234150

2 

M Starek J Krzek J Dechnik Separation and determination of rofecoxib and its degradation products by TLC chromatographyJ Anal Chem200964623

5 

G Subramanian S Pandey N Udupa RP-HPLC estimation of rofecoxib and tizanidine in combination tabletsIndian J Pharm Sc2004665699701

6 

N Spooner Dried blood spot sampling for quantitative bioanalysis: time for a revolution?Bioanalysis2010211178110.4155/bio.10.153

7 

AK Hamama J Ray RO Day JA Brien Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatographyJ Chromatographic Sci20054373515

8 

U Werner D Werner R Mundkowski M Gillich K Brune Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humansJ Chromatography B: Biomed Sc Appl200176018390

9 

CZ Matthews EJ Woolf BK Matuszewski Improved procedure for the the determination of rofecoxib in human plasma involving 96-well solid-phase extraction and fluorescence detectionJ Chromatography A20029491-28392

10 

N Navas R Urena LF Capitan-Vallvey Determination of celecoxib, rofecoxib, sodium diclofenac and niflumic acid in human serum samples by HPLC with DAD detectionChromatographia20086715561

11 

CM Chavez-Eng ML Constanzer BK Matuszewski Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detectionJ Chromatography B: Biomed Sci Appl200074813140

12 

M Amini MP Hamedani M Vosooghi M Nabavi A Shafiee Pre-column derivatization of rofecoxib for determination in serum by HPLC. Anal Bioanalytical Chem20053825126573

13 

E Demirtürk E Nemutlu S Şahin L Öner Development and validation of an HPLC method for determination of rofecoxib in bovine serum albumin microspheresTurkish J Chem202044364755

14 

S Sattari F Jamali High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasmaJ Pharm Pharmaceut Sci2000333128

15 

JY Hsieh L Lin BK Matuszewski High-throughput liquid chromatographic determination of rofecoxib in human plasma using a fully automated on-line solid-phase extraction systemJ liquid chromatog Relat Technol2001246799812

16 

E Woolf I Fu B Matuszewski Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detectionJ Chromatography B: Biomed Sci Appl199973022218

17 

A Savaşer Y Özkan CK Özkan Ç Taş SA Özkan RP‐HPLC Assay of Rofecoxib from Pharmaceutical Dosage Forms and Human Plasma and Its Drug Dissolution StudiesAnal lett20043718197

18 

CM Chavez-Eng ML Constanzer BK Matuszewski High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studiesJ Chromatography B2002767111746

19 

N Erk TG Altuntas Comparison of derivative spectrophotometric and liquid chromatographic methods for the determination of rofecoxibDie Pharmazie-An Int J Pharma Sci20045964539

20 

SJ Rajput MG Sankalia FT Patel Spectrofluorophotometric determination of rofecoxib and mosapride citrate in their individual dosage form. Indian J Pharma Sci2005675827

21 

C G Edmonds J A Mccloskey V A Edmonds A bibliography of combined liquid chromatography mass spectrometryBiomedical Mass Spectrometry198310423752

22 

DE Games High-performance liquid chromatography/mass spectrometry (HPLC/MS)Anal Bioanal Chem198321139

23 

PJ Arpino Ten years of liquid chromatography-mass spectrometryJ Chromatography A19853231311

24 

VL Talroze VE Skurat GV Karpov Application of a mass spectrometer with a capillary inlet system as a detector in a liquid chromatographyRussian J Phys Chem USSR1969432241

25 

T Radhakrishna DS Rao GO Reddy LC determination of rofecoxib in bulk and pharmaceutical formulationsJ Pharm Biomed Anal200126461745

26 

MA Shehata A Ashour NY Hassan AS Fayed BA El-Zeany Liquid chromatography and chemometric methods for determination of rofecoxib in presence of its photodegradate and alkaline degradation productsAnal Chimica acta200451912330

27 

M Gandhimathi TK Ravi SJ Varghese Simultaneous LC determination of tizanidine and rofecoxib in tabletsJ Pharm Biomed Anal20053711838

28 

N Kaul SR Dhaneshwar H Agrawal A Kakad B Patil Application of HPLC and HPTLC for the simultaneous determination of tizanidine and rofecoxib in pharmaceutical dosage formJ Pharm Biomed Anal20053712738

29 

KE Nagoji MK Kumar S Mathivanan N M Kumar M Rao A new reverse phase high performance liquid chromatographic method for analysis of rofecoxib in tabletsIndian J Pharm Sci200466112960

30 

PN Pai H Khan Hplc method for simultaneous estimation of rofecoxib and tizanidine hydrochloride in tablets. Indian J Pharm Sci2005675049

31 

G Subramanian R Shetty S Agarwal S Pandey N Udupa Simultaneous reverse phase HPLC estimation of paracetamol and rofecoxib in tablets. Indian J Pharmaceutical Sci20056724756

32 

JK Lalla PD Hamrapurkar SP Yadav PM Vyas An improved HPLC method of analysis of rofecoxib. Indian J Pharm Sci20046633878

33 

YK Tadikonda M Dhanalakshmi RP-HPLC Method Development and Validation of Rofecoxib in Bulk and Dosage FormInt J Adv Pharma Biotechnol20195215

34 

T Ravi M Gandhimathi K Sireesha S Jacob HPTLC method for the simultaneous estimation of Tizanidine and Rofecoxib in tablets. Indian J Pharm Sci20066822346

35 

N Kaul SR Dhaneshwar H Agrawal A Kakad B Patil Application of HPLC and HPTLC for the simultaneous determination of tizanidine and rofecoxib in pharmaceutical dosage formJ Pharm Biomed Anal20053712738

36 

UD Pawar AV Sulebhavikar AV Naik SG Pingale KV Mangaonkar Simultaneous determination of rofecoxib and tizanidine by HPTLCJ Chem20096295302



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.